185 related articles for article (PubMed ID: 25525332)
1. Clinicopathological significance and potential drug target of RUNX3 in breast cancer.
Yu YY; Chen C; Kong FF; Zhang W
Drug Des Devel Ther; 2014; 8():2423-30. PubMed ID: 25525332
[TBL] [Abstract][Full Text] [Related]
2. An early biomarker and potential therapeutic target of RUNX 3 hypermethylation in breast cancer, a system review and meta-analysis.
Lu DG; Ma YM; Zhu AJ; Han YW
Oncotarget; 2017 Mar; 8(13):22166-22174. PubMed ID: 27825140
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.
Xu L; Lan H; Su Y; Li J; Wan J
Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616
[TBL] [Abstract][Full Text] [Related]
4. [Correlation between the methylation status of Runx3 gene and positive expression of estrogen receptor in breast cancer].
Yan Z; Gao S; Wu X; Liu H
Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):240-4. PubMed ID: 25975905
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of RUNX3 gene hypermethylation in hepatocellular carcinoma.
Yang Y; Ye Z; Zou Z; Xiao G; Luo G; Yang H
Tumour Biol; 2014 Oct; 35(10):10333-40. PubMed ID: 25037468
[TBL] [Abstract][Full Text] [Related]
6. The clinicopathological significance of RUNX3 hypermethylation and mRNA expression in human breast cancer, a meta-analysis.
Song XY; Li BY; Zhou EX; Wu FX
Onco Targets Ther; 2016; 9():5339-47. PubMed ID: 27616890
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
Huang R; Ding P; Yang F
Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
[TBL] [Abstract][Full Text] [Related]
8. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
9. RUNX3 Epigenetic Inactivation Is Associated With Estrogen Receptor Positive Breast Cancer.
Liu H; Yan Z; Yin Q; Cao K; Wei Y; Rodriguez-Canales J; Ma D; Wu Y
J Histochem Cytochem; 2018 Oct; 66(10):709-721. PubMed ID: 30133331
[TBL] [Abstract][Full Text] [Related]
10. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
Su Y; Wang X; Li J; Xu J; Xu L
Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
[TBL] [Abstract][Full Text] [Related]
11. Association of promoter methylation of RUNX3 gene with the development of esophageal cancer: a meta analysis.
Wang Y; Qin X; Wu J; Qi B; Tao Y; Wang W; Liu F; Li H; Zhao B
PLoS One; 2014; 9(9):e107598. PubMed ID: 25229459
[TBL] [Abstract][Full Text] [Related]
12. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer.
Lau QC; Raja E; Salto-Tellez M; Liu Q; Ito K; Inoue M; Putti TC; Loh M; Ko TK; Huang C; Bhalla KN; Zhu T; Ito Y; Sukumar S
Cancer Res; 2006 Jul; 66(13):6512-20. PubMed ID: 16818622
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance and association of RUNX3 hypermethylation frequency with colorectal cancer: a meta-analysis.
Mu WP; Wang J; Niu Q; Shi N; Lian HF
Onco Targets Ther; 2014; 7():1237-45. PubMed ID: 25053885
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer.
Chen W; Gao N; Shen Y; Cen JN
J Gastroenterol Hepatol; 2010 Apr; 25(4):823-31. PubMed ID: 20492341
[TBL] [Abstract][Full Text] [Related]
15. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
[TBL] [Abstract][Full Text] [Related]
16. A systematic review and meta-analysis of runt-related transcription factor 3 gene promoter hypermethylation and risk of gastric cancer.
Xia Y; Zhang M; Zhang X; Liu X
J Cancer Res Ther; 2014 Dec; 10 Suppl():310-3. PubMed ID: 25693942
[TBL] [Abstract][Full Text] [Related]
17. Demethylation of RUNX3 by vincristine in colorectal adenocarcinoma cells.
Moon JW; Lee SK; Lee JO; Kim JH; Kim N; Kim J; Kim HS; Park SH
Anticancer Res; 2014 Jan; 34(1):133-40. PubMed ID: 24403453
[TBL] [Abstract][Full Text] [Related]
18. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker.
Nishio M; Sakakura C; Nagata T; Komiyama S; Miyashita A; Hamada T; Kuryu Y; Ikoma H; Kubota T; Kimura A; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Ida H; Ito K; Chiba T; Ito Y; Otsuji E
Anticancer Res; 2010 Jul; 30(7):2673-82. PubMed ID: 20682997
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of determining the hypermethylation of the RUNX3 gene promoter and its cohypermethylation with the BRCA1 gene for patients with breast cancer.
Rossokha Z; Fishchuk L; Lobanova O; Vershyhora V; Medvedieva N; Cheshuk V; Vereshchako R; Podolska S; Gorovenko N
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11919-11927. PubMed ID: 37420018
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma.
Long C; Yin B; Lu Q; Zhou X; Hu J; Yang Y; Yu F; Yuan Y
Cancer Invest; 2007 Dec; 25(8):685-90. PubMed ID: 18058463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
